RN7SL22P

Across TCGA pan-cancer cohorts, RN7SL22P RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RN7SL22P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RN7SL22P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RN7SL22P is over-expressed in tumor, although a few such as BRCA and ESCA show the opposite, repressed pattern.

KIRC, HNSC, and BRCA are the cancer types where RN7SL22P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RN7SL22P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.094	<.001	5	view →
HNSC	Male	II,III,IV	+0.059	.024	4	view →
BRCA	Female	All	−0.044	.008	2	view →
ESCA	All	All	−0.157	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

RN7SL22P–KIRC

Open the KIRC breakdown →